论文部分内容阅读
目的与单用甘精胰岛素治疗对比分析,探讨瑞格列奈联合甘精胰岛素对2型糖尿病患者胰岛素分泌及胰岛β细胞功能的影响。方法选取安阳市人民医院收治的100例2型糖尿病患者作为研究对象,随机分为观察组与对照组,每组50例。对照组采用甘精胰岛素治疗,观察组予以瑞格列奈联合甘精胰岛素治疗,两组患者均连续治疗3个月。比较两组血糖达标时间、胰岛素用量、血糖水平[空腹血糖(FPG)、餐后2 h血糖(2h PG)]、空腹胰岛素(FINS)分泌水平、胰岛β细胞功能(HOMA-β)与胰岛素抵抗指数(HOMA-IR)。结果两组血糖达标所需时间相比,差异无统计学意义(P>0.05);观察组胰岛素日用量低于对照组,差异有统计学意义(P<0.05);治疗后,两组血糖水平均降低,观察组FPG、2h PG水平显著低于对照组,差异有统计学意义(P<0.05);治疗后,两组FINS、HOMA-β均升高,而HOMA-IR水平降低,且观察组更为显著,差异有统计学意义(P<0.05)。结论 2型糖尿病患者采用瑞格列奈联合甘精胰岛素治疗疗效确切,显著优于单一用药,在减少胰岛素用量的前提下,显著改善患者的胰岛β细胞功能,控制患者的血糖水平。
Objective To compare the effects of repaglinide and insulin glargine on insulin secretion and islet β-cell function in patients with type 2 diabetes mellitus (T2DM). Methods 100 cases of type 2 diabetes mellitus treated in Anyang People’s Hospital were randomly divided into observation group and control group with 50 cases in each group. The control group was treated with insulin glargine, and the observation group was treated with repaglinide and insulin glargine. The patients in both groups were treated continuously for 3 months. The blood glucose up-time, insulin dosage, blood glucose level [fasting blood glucose (FPG), postprandial 2h blood glucose (2h PG)], fasting insulin (FINS) secretion, pancreatic βcell function (HOMA-β) and insulin resistance Index (HOMA-IR). Results Compared with the control group, the daily dosage of insulin in the observation group was lower than that in the control group (P <0.05). After treatment, the blood glucose level (P <0.05). After treatment, the levels of FINS and HOMA-β in both groups increased and the levels of HOMA-IR decreased, and the levels of FPG and 2h PG in the observation group were significantly lower than those in the control group Group was more significant, the difference was statistically significant (P <0.05). Conclusion The treatment with repaglinide and insulin glargine in patients with type 2 diabetes mellitus is more effective than single drug treatment. It can significantly improve the pancreatic β-cell function and control the blood glucose level of patients under the premise of reducing insulin dosage.